Table 3.

Univariate and multivariate analyses of overall survival in the training set.

Characteristic	Univariate analysis		Multivariate Cox regression analysis
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age (years)	1.276 (0.863–1.888)	0.222
Histological type	0.271 (0.100–0.738)	0.011*	0.265 (0.091–0.765)	0.014*
Tumor grade	1.359 (1.009–1.830)	0.044*	0.936 (0.658–1.331)	0.714
T stage	1.843 (1.465–2.319)	0.000*	1.085 (0.842–1.400)	0.528
N stage	2.426 (2.036–2.891)	0.000*	2.471 (2.016–3.029)	0.000*
Clinical stage	4.200 (2.988–5.960)	0.000*
Molecular Subtype	1.206 (1.052–1.383)	0.007*	1.243 (1.072–1.440)	0.004*
ER	0.671 (0.449–1.004)	0.052
PR	0.640 (0.433–0.945)	0.025*
HER2	1.745 (1.175–2.593)	0.006*
Ki67	1.956 (1.210–3.163)	0.006*
Adjuvant chemotherapy	1.596 (0.854–2.986)	0.143
Endocrine Therapy	0.791 (0.536–1.167)	0.237
Radiotherapy	1.836 (1.232–2.735)	0.003*	0.775 (0.505–1.189)	0.244
Target Therapy	0.851 (0.373–1.943)	0.702
SIS group	1.538 (1.032–2.292)	0.034*	1.543 (1.031–2.310)	0.035*

^*P < 0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; SIS, Systemic inflammation score.